LAVA Cost Of Revenue vs Gross Profit Analysis

LVTX Stock

USD 1.60 0.05 3.23%

LAVA Therapeutics financial indicator trend analysis is infinitely more than just investigating LAVA Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether LAVA Therapeutics is a good investment. Please check the relationship between LAVA Therapeutics Cost Of Revenue and its Gross Profit accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LAVA Therapeutics NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Cost Of Revenue vs Gross Profit

Cost Of Revenue vs Gross Profit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of LAVA Therapeutics Cost Of Revenue account and Gross Profit. At this time, the significance of the direction appears to have pay attention.

The correlation between LAVA Therapeutics' Cost Of Revenue and Gross Profit is -0.96. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Gross Profit in the same time period over historical financial statements of LAVA Therapeutics NV, assuming nothing else is changed. The correlation between historical values of LAVA Therapeutics' Cost Of Revenue and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of LAVA Therapeutics NV are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Cost Of Revenue i.e., LAVA Therapeutics' Cost Of Revenue and Gross Profit go up and down completely randomly.

Correlation Coefficient

-0.96

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on LAVA Therapeutics income statement and represents the costs associated with goods and services LAVA Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of LAVA Therapeutics NV minus its cost of goods sold. It is profit before LAVA Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most indicators from LAVA Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into LAVA Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LAVA Therapeutics NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Tax Provision is likely to drop to about 158.4 K in 2024. Selling General Administrative is likely to drop to about 9.5 M in 2024

	2021	2022	2023	2024 (projected)
Interest Expense	625K	82K	232K	300.7K
Depreciation And Amortization	558K	504K	1.3M	1.3M

Interest Expense Depreciation And Amortization

LAVA Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.88	0.92	0.78	0.97	0.97	0.9	0.59	-0.93	-0.87	0.9	0.96	0.89	0.75	0.93	0.92	1.0	0.76	0.66	0.89	0.76	0.94	0.97	0.87	0.99	0.87
Short Long Term Debt Total	0.88		0.85	0.85	0.79	0.87	0.99	0.5	-0.72	-0.93	0.91	0.77	0.99	0.83	0.88	0.98	0.87	0.83	0.9	0.9	0.79	0.84	0.92	0.9	0.81	0.89
Other Current Liab	0.92	0.85		0.91	0.84	0.83	0.83	0.84	-0.82	-0.81	0.87	0.85	0.87	0.79	0.84	0.88	0.91	0.93	0.77	0.9	0.72	1.0	0.89	0.91	0.88	0.8
Total Current Liabilities	0.78	0.85	0.91		0.62	0.72	0.84	0.83	-0.56	-0.85	0.91	0.61	0.82	0.67	0.8	0.88	0.77	0.99	0.92	0.94	0.83	0.9	0.84	0.97	0.68	0.86
Total Stockholder Equity	0.97	0.79	0.84	0.62		0.94	0.81	0.47	-0.98	-0.76	0.78	1.0	0.83	0.73	0.86	0.82	0.98	0.61	0.5	0.77	0.62	0.87	0.9	0.73	1.0	0.75
Net Tangible Assets	0.97	0.87	0.83	0.72	0.94		0.9	0.47	-0.9	-0.87	0.92	0.91	0.85	0.67	0.93	0.93	0.98	0.67	0.63	0.9	0.82	0.85	0.98	0.85	0.96	0.91
Property Plant And Equipment Net	0.9	0.99	0.83	0.84	0.81	0.9		0.46	-0.73	-0.96	0.93	0.79	0.97	0.76	0.92	0.99	0.89	0.8	0.88	0.92	0.84	0.83	0.95	0.91	0.84	0.93
Current Deferred Revenue	0.59	0.5	0.84	0.83	0.47	0.47	0.46		-0.5	-0.47	0.62	0.49	0.52	0.56	0.48	0.56	0.58	0.87	0.59	0.68	0.51	0.82	0.56	0.74	0.52	0.52
Net Debt	-0.93	-0.72	-0.82	-0.56	-0.98	-0.9	-0.73	-0.5		0.64	-0.7	-0.99	-0.78	-0.77	-0.75	-0.76	-0.94	-0.57	-0.41	-0.69	-0.51	-0.85	-0.84	-0.66	-0.97	-0.66
Retained Earnings	-0.87	-0.93	-0.81	-0.85	-0.76	-0.87	-0.96	-0.47	0.64		-0.95	-0.72	-0.89	-0.59	-0.97	-0.94	-0.86	-0.8	-0.87	-0.94	-0.91	-0.81	-0.94	-0.93	-0.8	-0.96
Accounts Payable	0.9	0.91	0.87	0.91	0.78	0.92	0.93	0.62	-0.7	-0.95		0.74	0.86	0.61	0.94	0.97	0.9	0.85	0.84	1.0	0.96	0.87	0.97	0.98	0.83	0.99
Cash	0.96	0.77	0.85	0.61	1.0	0.91	0.79	0.49	-0.99	-0.72	0.74		0.83	0.77	0.82	0.8	0.96	0.61	0.49	0.73	0.56	0.87	0.87	0.7	0.99	0.7
Non Current Assets Total	0.89	0.99	0.87	0.82	0.83	0.85	0.97	0.52	-0.78	-0.89	0.86	0.83		0.89	0.85	0.95	0.88	0.82	0.86	0.85	0.7	0.86	0.9	0.86	0.84	0.83
Non Currrent Assets Other	0.75	0.83	0.79	0.67	0.73	0.67	0.76	0.56	-0.77	-0.59	0.61	0.77	0.89		0.56	0.77	0.74	0.72	0.67	0.63	0.37	0.78	0.69	0.65	0.73	0.55
Other Assets	0.93	0.88	0.84	0.8	0.86	0.93	0.92	0.48	-0.75	-0.97	0.94	0.82	0.85	0.56		0.92	0.93	0.74	0.75	0.93	0.89	0.85	0.97	0.9	0.89	0.94
Long Term Debt	0.92	0.98	0.88	0.88	0.82	0.93	0.99	0.56	-0.76	-0.94	0.97	0.8	0.95	0.77	0.92		0.92	0.84	0.87	0.96	0.87	0.87	0.97	0.95	0.86	0.95
Cash And Short Term Investments	1.0	0.87	0.91	0.77	0.98	0.98	0.89	0.58	-0.94	-0.86	0.9	0.96	0.88	0.74	0.93	0.92		0.75	0.65	0.89	0.76	0.93	0.97	0.86	0.99	0.87
Net Receivables	0.76	0.83	0.93	0.99	0.61	0.67	0.8	0.87	-0.57	-0.8	0.85	0.61	0.82	0.72	0.74	0.84	0.75		0.9	0.89	0.75	0.91	0.79	0.94	0.66	0.78
Common Stock Shares Outstanding	0.66	0.9	0.77	0.92	0.5	0.63	0.88	0.59	-0.41	-0.87	0.84	0.49	0.86	0.67	0.75	0.87	0.65	0.9		0.85	0.78	0.74	0.76	0.89	0.55	0.81
Non Current Liabilities Total	0.89	0.9	0.9	0.94	0.77	0.9	0.92	0.68	-0.69	-0.94	1.0	0.73	0.85	0.63	0.93	0.96	0.89	0.89	0.85		0.95	0.89	0.96	0.99	0.81	0.98
Capital Lease Obligations	0.76	0.79	0.72	0.83	0.62	0.82	0.84	0.51	-0.51	-0.91	0.96	0.56	0.7	0.37	0.89	0.87	0.76	0.75	0.78	0.95		0.72	0.89	0.92	0.68	0.98
Other Current Assets	0.94	0.84	1.0	0.9	0.87	0.85	0.83	0.82	-0.85	-0.81	0.87	0.87	0.86	0.78	0.85	0.87	0.93	0.91	0.74	0.89	0.72		0.9	0.91	0.9	0.8
Other Stockholder Equity	0.97	0.92	0.89	0.84	0.9	0.98	0.95	0.56	-0.84	-0.94	0.97	0.87	0.9	0.69	0.97	0.97	0.97	0.79	0.76	0.96	0.89	0.9		0.93	0.93	0.96
Total Liab	0.87	0.9	0.91	0.97	0.73	0.85	0.91	0.74	-0.66	-0.93	0.98	0.7	0.86	0.65	0.9	0.95	0.86	0.94	0.89	0.99	0.92	0.91	0.93		0.78	0.95
Net Invested Capital	0.99	0.81	0.88	0.68	1.0	0.96	0.84	0.52	-0.97	-0.8	0.83	0.99	0.84	0.73	0.89	0.86	0.99	0.66	0.55	0.81	0.68	0.9	0.93	0.78		0.8
Property Plant And Equipment Gross	0.87	0.89	0.8	0.86	0.75	0.91	0.93	0.52	-0.66	-0.96	0.99	0.7	0.83	0.55	0.94	0.95	0.87	0.78	0.81	0.98	0.98	0.8	0.96	0.95	0.8

Click cells to compare fundamentals

LAVA Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for LAVA Stock Analysis

When running LAVA Therapeutics' price analysis, check to measure LAVA Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LAVA Therapeutics is operating at the current time. Most of LAVA Therapeutics' value examination focuses on studying past and present price action to predict the probability of LAVA Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LAVA Therapeutics' price. Additionally, you may evaluate how the addition of LAVA Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

LAVA Cost Of Revenue vs Gross Profit Analysis

Cost Of Revenue vs Gross Profit

Cost Of Revenue vs Gross Profit Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Gross Profit

LAVA Therapeutics fundamental ratios Correlations

LAVA Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for LAVA Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Other Current Assets	+ 1.0	Other Current Liab
Cash	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Liabilities Total	+ 1.0	Accounts Payable
Net Invested Capital	+ 0.99	Total Assets

Cash	- 0.99	Net Debt
Net Debt	- 0.98	Total Stockholder Equity
Other Assets	- 0.97	Retained Earnings
Net Invested Capital	- 0.97	Net Debt
Property Plant And Equipment Gross	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Property Plant And Equipment Net